PharmaMar to present new data on its compounds at AACR 2023 Congress

PharmaMar (MSE:PHM) has announced today four new abstracts from clinical trials of its compounds Zepzelca® (lurbinectedin), ecubectedin (PM14) and PM534 at the Annual Meeting of the American Association for Cancer Research (AACR), being held in Orlando, Florida (USA) from April 14-19. Among the studies to be presented, the abstract entitled ” Lurbinectedin shows potent activity in all four molecular subtypes of small cell lung cancer (SCLC) and POU2F3 and SFLN11 are biomarkers for a better response“, presents lurbinectedin activity results obtained in a panel of tumor cells that express the four transcription factors (ASCL1, NEUROD1, YAP1, POU2F3) which permit the molecular classification of SCLC. Moreover, in both in vitro and in vivo studies, as well as in biopsies obtained from patients, a possible predictive biomarker of response to lurbinectedin is identified, SLFN11. Two abstracts will be presented at the congress on PharmaMar’s new marine-derived anti-tumor compound, PM534, which is obtained by chemical synthesis and is currently in Phase I clinical development. The first of the abstracts, entitled “PM534 is a novel microtubule-destabilizing agent with high affinity and potent antineoplastic properties“, demonstrates by X-ray crystallography that PM534 binds to its target, tubulin, inducing a strong antitumor effect in vitro and in vivo. This research has been carried out in collaboration with CSIC (Spanish National Research Council) researchers. The second, entitled “The novel antitubulin agent PM534 exhibits potent antitumoral and antiangiogenic properties in vivo and in vitro“, shows that, as a result of its high affinity for tubulin, it acts by destabilizing the microtubular network in the tumor cell, resulting in potent antitumor activity in vitro and in vivo. In addition, PM534 is a potent inhibitor of angiogenesis, which prevents the formation of blood vessels necessary for tumor growth. Finally, PharmaMar will present the abstract “Ecubectedin is a novel transcriptional inhibitor that displays potent antitumor effects in vivo and in vitro“. This antitumor compound induces tumor cell death through apoptosis by inhibiting the activated transcription. This mechanism of action results in a very potent antitumor activity in vitro and in vivo models. Ecubectedin is currently in Phase II clinical development. PharmaMar’s abstracts at AACR 2023 PRODUCTTITLELEAD AUTHORABSTRACT Zepzelca® (lurbinectedin)Lurbinectedin shows potent activity in all four molecular subtypes of small cell lung cancer (SCLC) and POU2F3 and SFLN11 are biomarkers for a better responseEva María Garrido-Martín, PhDABSTRACT: 6247   POSTER SESION: Experimental and Molecular Therapeutics PM534PM534 is a novel microtubule-destabilizing agent with high affinity and potent antineoplastic propertiesEva María Garrido-Martín, PhDABSTRACT: 6239   POSTER SESION: Experimental and Molecular Therapeutics PM534The novel antitubulin agent PM534 exhibits potent antitumoral and antiangiogenic properties in vivo and in vitroEva María Garrido-Martín, PhDABSTRACT: 6243   POSTER SESION: Experimental and Molecular Therapeutics Ecubectedin (PM14)Ecubectedin is a novel transcriptional inhibitor that displays potent antitumor effects in vivo and in vitroEva María Garrido-Martín, PhDABSTRACT: 1622   POSTER SESION: Experimental and Molecular Therapeutics

The release as fetched from its publisher. pharmamar.com ↗